Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Room Ba304, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
J Nucl Cardiol. 2013 Apr;20(2):227-33. doi: 10.1007/s12350-012-9657-z. Epub 2012 Nov 28.
There are no data regarding the long-term prognostic value of single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in obese patients. The aim of this study was to examine the value of stress (99m)Tc-tetrofosmin MPI findings for the prediction of very long-term outcome in obese patients.
The study population consisted of 261 patients with a body mass index ≥30 kg/m(2) who underwent exercise or pharmacological stress (99m)Tc-tetrofosmin MPI for the assessment of known or suspected coronary artery disease. Endpoints during follow-up were all-cause mortality, cardiac death, nonfatal infarction, and coronary revascularization. Kaplan-Meier survival cures were constructed and univariate and multivariate analyses were performed to identify predictors of very long-term outcome.
The mean age was 59 ± 10 years, 42% of the patients was male, and the body mass index was on average 37 ± 7 kg/m(2). MPI findings were normal in 109 patients (42%). Myocardial perfusion abnormalities were fixed in 62 patients (24%) and reversible in 90 patients (34%). During a median 12-year follow-up, 91 (35%) patients died, and 27 (10%) had a nonfatal myocardial infarction. Survival curves were compared using the log-rank test at subsequent follow-up durations. Obese patients with a normal stress (99m)Tc-tetrofosmin study had a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test was performed.
Stress (99m)Tc-tetrofosmin MPI provides valuable prognostic information for the prediction of outcome in obese patients. Obese patients with a normal stress (99m)Tc-tetrofosmin study have a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test is performed.
目前尚无关于单光子发射计算机断层扫描(SPECT)心肌灌注成像(MPI)在肥胖患者中的长期预后价值的数据。本研究旨在探讨应激(99m)Tc-四氮甲基吡嗪 MPI 检查结果对肥胖患者长期预后的预测价值。
本研究纳入了 261 名体重指数(BMI)≥30kg/m2的患者,他们接受运动或药物负荷(99m)Tc-四氮甲基吡嗪 MPI 检查以评估已知或疑似冠状动脉疾病。随访期间的终点事件为全因死亡率、心源性死亡率、非致死性心肌梗死和冠状动脉血运重建。构建 Kaplan-Meier 生存曲线,并进行单因素和多因素分析以确定长期预后的预测因素。
患者的平均年龄为 59±10 岁,42%为男性,平均 BMI 为 37±7kg/m2。109 名患者(42%)的 MPI 结果正常。62 名患者(24%)存在固定的心肌灌注异常,90 名患者(34%)存在可逆性心肌灌注异常。在中位 12 年的随访期间,91 名患者(35%)死亡,27 名患者(10%)发生非致死性心肌梗死。通过后续随访期间的对数秩检验比较生存曲线。与 MPI 异常的患者相比,应激(99m)Tc-四氮甲基吡嗪检查结果正常的肥胖患者在检查后 6 年内具有显著更好的预后。
应激(99m)Tc-四氮甲基吡嗪 MPI 检查为肥胖患者的预后预测提供了有价值的预后信息。与 MPI 异常的患者相比,应激(99m)Tc-四氮甲基吡嗪检查结果正常的肥胖患者在检查后 6 年内具有显著更好的预后。